Saturday, 20.06.2026, Calendar Week 25, 171st day of the year, 194 days remaining until EoY.

Newsfeed

This area is a possible form of presentation for the integration of news sources relating to listed companies.

The presentation level is a template based on short news services, where users can get a quick overview of the latest news. The detailed views enable further research if interested.

This newsfeed is a compilation of current news from direct connections of TopTier NewsWire services related to listed companies. This feed is for demonstration purposes only. Sector-specific news, public relations and product information can be accessed via the GICS portals > Sector Intelligence section.

BE0974358906

Reset filter

Do you already know our new terminal view? Click here.

FIGI: BBG00X7DCB76

NYXH

Nyxoah S.A.

GICS: Health Care · SECTOR: EQTY · SUB-SECTOR: Medtech · THEMEFOLIO: $HLTH

NAME

Nyxoah S.A.

ISIN

BE0974358906

TICKER

NYXH

MIC

XNAS

REUTERS

NYXH.BR

BLOOMBERG

NYXH US

Fri, 19.06.2026 Nyxoah

Newsfeed

Invitation to attend the extraordinary shareholders’ meeting of the Company to be held on July 9, 2026 | Nyxoah S.A.

Publication relating to transparency notifications | Nyxoah S.A.

Nyxoah Receives $15 Million from the European Investment Bank | Nyxoah S.A.

Nyxoah’s Genio® Wins Prix Galien UK 2026 Award for Best Medical Technology | Nyxoah S.A.

Information on the total number of voting rights and shares | Nyxoah S.A.

$110 Million in Aggregate Financings to Accelerate Genio's U.S. Commercial Launch | Nyxoah S.A.

Nyxoah Announces Closing of Underwritten Public Offering | Nyxoah S.A.

Nyxoah Announces Pricing of $95 Million Underwritten Public Offering | Nyxoah S.A.

XFRA: INSTRUMENT_SUSPENSION - BE0974358906 | Nyxoah S.A.

Nyxoah Announces Proposed Offering of Ordinary Shares | Nyxoah S.A.

Nyxoah Enters New Chapter of Long Term Value Creation | Nyxoah S.A.

Information on the total number of voting rights and shares | Nyxoah S.A.

Nyxoah Welcomes the Flemish Investors Federation (VFB) at LégiaPark following Q1 2026 Results and U.S. Commercial Momentum | Nyxoah S.A.

Nyxoah Reports First Quarter 2026 Financial and Operating Results | Nyxoah S.A.

Invitation to attend the annual and the extraordinary shareholders’ meetings of the Company to be held on June 10, 2026 | Nyxoah S.A.

Nyxoah to Release First Quarter 2026 Financial Results on May 12, 2026 | Nyxoah S.A.

Publication relating to transparency notifications | Nyxoah S.A.

Nyxoah Reports Fourth Quarter and Full Year 2025 Financial and Operating Results | Nyxoah S.A.

Publication relating to transparency notification | Nyxoah S.A.

Nyxoah to Participate in the Oppenheimer 36th Annual Healthcare MedTech & Services Conference | Nyxoah S.A.

Nyxoah to Release Fourth Quarter and Full Year 2025 Financial Results on March 19, 2026 | Nyxoah S.A.

Publication relating to transparency notifications | Nyxoah S.A.

Information on the total number of voting rights and shares | Nyxoah S.A.

Nyxoah Announces the Signature of a Memorandum of Understanding with Sheikh Shakhbout Medical City Hospital to Improve OSA Therapy Management and Accelerate Access to Genio in the Middle East | Nyxoah S.A.

Nyxoah Invests In Further Expanding Its Belgian Manufacturing Capacity To Support Its Worldwide Growth | Nyxoah S.A.

Nyxoah Announces Preliminary Results for the Fourth Quarter and Full Year 2025 and Provides Revenue Guidance for the First Quarter of 2026 | Nyxoah S.A.

Publication relating to transparency notification | Nyxoah S.A.

Nyxoah to Present at the 44th Annual J.P. Morgan Healthcare Conference | Nyxoah S.A.

Nyxoah Announces Issuance of First Tranche of Convertible Bonds | Nyxoah S.A.

Nyxoah Announces Commercial Launch of Genio® Breakthrough Therapy in the Netherlands | Nyxoah S.A.

Publication relating to transparency notifications | Nyxoah S.A.

Nyxoah to Participate in the Piper Sandler 37th Annual Healthcare Conference | Nyxoah S.A.

Nyxoah’s Genio® Therapy Receives Significant 2026 Medicare Reimbursement Increases Under Final CMS Rule | Nyxoah S.A.

Information on the total number of voting rights and shares | Nyxoah S.A.

Nyxoah Obtient des Engagements de Financement pouvant atteindre U.S. $77 Millions pour Supporter la Commercialisation de Genio aux États-Unis | Nyxoah S.A.

Nyxoah Secures Financing Commitments of up to U.S. $77 Million to Drive U.S. Commercialization of Genio | Nyxoah S.A.

Nyxoah Secures Financing Commitments of up to U.S. $77 Million to Drive U.S. Commercialization of Genio | Nyxoah S.A.

Nyxoah Reports Third Quarter 2025 Financial and Operating Results | Nyxoah S.A.

Nyxoah to Participate in the Stifel 2025 Healthcare Conference | Nyxoah S.A.

Nyxoah to Release Third Quarter 2025 Financial Results on November 13, 2025 | Nyxoah S.A.

Nyxoah Announces First U.S. Commercial Patients Implanted with Genio® System | Nyxoah S.A.

Publication relating to transparency notifications | Nyxoah S.A.

Nyxoah Provides an Update on Expanded Middle East Presence | Nyxoah S.A.

Nyxoah reicht Klage wegen Patentverletzung gegen Inspire Medical Systems, Inc. ein | Nyxoah S.A.

Nyxoah Files Patent Infringement Lawsuit Against Inspire Medical Systems, Inc. | Nyxoah S.A.

Nyxoah Files Patent Infringement Lawsuit Against Inspire Medical Systems, Inc. | Nyxoah S.A.

Publication relating to transparency notifications | Nyxoah S.A.

Nyxoah Announces Upcoming Investor Events | Nyxoah S.A.

Nyxoah gibt Finanzergebnisse und operatives Update für das zweite Quartal bekannt | Nyxoah S.A.

Nyxoah Reports Second Quarter Financial and Operating Results | Nyxoah S.A.